B7-H6 Protein (AA 25-262) (His tag)
-
- Target Alle B7-H6 (NCR3LG1) Proteine anzeigen
- B7-H6 (NCR3LG1) (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 (NCR3LG1))
- Protein-Typ
- Recombinant
- Biologische Aktivität
- Active
- Proteineigenschaft
- AA 25-262
-
Spezies
- Human
-
Quelle
- HEK-293 Cells
- Aufreinigungstag / Konjugat
- Dieses B7-H6 Protein ist gelabelt mit His tag.
- Sequenz
- AA 25-262
- Reinheit
- >90 % as determined by SDS-PAGE.
- Endotoxin-Niveau
- Less than 1.0 EU per μg by the LAL method.
- Top Product
- Discover our top product NCR3LG1 Protein
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4
- Handhabung
- Please avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
-
- Target
- B7-H6 (NCR3LG1) (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 (NCR3LG1))
- Andere Bezeichnung
- B7-H6 (NCR3LG1 Produkte)
- Synonyme
- B7-H6 Protein, B7H6 Protein, DKFZp686O24166 Protein, natural killer cell cytotoxicity receptor 3 ligand 1 Protein, NCR3LG1 Protein
- Hintergrund
- The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene, however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.
- Molekulargewicht
- 28.6 kDa
-